Roche and its subsidiary, Tib Molbiol, confirm that it has tests for research use that identify the SARS-CoV-2 subvariants of concern, Omicron: BA.1, BA.1.1, BA.2, BA.2.2, BA.3 and Delta
The sale is expected to close in the first quarter of 2022
Urban, semi-urban and remote corners of the country will be catered using drone delivery technology
Takes charge to lead business innovation, strategy, alliance & partnerships
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
It plans to add over 1000 employees over the next six months
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
The agreement could rise to $900 million if key commercial milestones are met
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
Subscribe To Our Newsletter & Stay Updated
